

Saudi Arabia.

18% of the population. One Vision. Continuous adversarial verification.

Saudi Arabia carries **18% diabetes prevalence** — one of the highest in the world. The Ministry of Health has named lower-extremity amputation reduction a stated **Vision 2030 priority**. AimwellBio runs adversarial intelligence scoped to SFDA approvals, MOHAP procurement cycles, MOH formulary decisions, and the GCC + MENA manufacturing layer that supplies them. **Wound care + diabetes are tracked together** because the diabetic foot ulcer is where the two indications collide — and where Vision 2030 outcomes are won or lost.

<p>COMBINED SIGNALS</p> <p>182</p> <p>90 wound-care · 96 diabetes</p>	<p>SOVEREIGN ANCHORS</p> <p>6</p> <p>KSA · GCC · MENA manufacturers</p>	<p>INDICATION VECTORS</p> <p>2</p> <p>Wound Care + Diabetes — both Vision 2030 priorities</p>	<p>REFRESH CADENCE</p> <p>Live</p> <p>Wound Care /report/wound-care · Diabetes /report/diabetes</p>
--	--	--	--

01 · THE MANDATE

The Vision 2030 Mandate.

Three converging policy vectors

<p>I · PREVALENCE</p> <p>Diabetes prevalence</p> <p>18% of the KSA population. Among the highest globally. The number is the policy.</p>	<p>II · ENDPOINT</p> <p>The Amputation Vector</p> <p>Diabetic foot ulcer is the operational endpoint where diabetes becomes wound care. MOH outcome targets fall here. Tracking the indication intersection is non-optional.</p>	<p>III · SUPPLY</p> <p>Procurement Sovereignty</p> <p>KSA + GCC manufacturing localization is no longer aspirational. Six anchored manufacturers under continuous monitoring.</p>
---	---	--

Sovereign Manufacturing — under continuous adversarial verification.

6 manufacturers · KSA / GCC / MENA

SPIMACO

Riyadh, SA

KSA

Saudi Pharmaceutical Industries & Medical Appliances Corp.; primary Saudi-domiciled manufacturer with active diabetes-formulary portfolio aligned to MOH procurement.

</atlas?company=SPIMACO>

Tabuk Pharmaceuticals

Tabuk, SA

KSA

Saudi diabetes-care manufacturer headquartered in Tabuk; SFDA-aligned production for Vision 2030 sovereign-supply mandates.

</atlas?company=Tabuk%20Pharmaceuticals>

Jamjoom Pharma

Jeddah, SA

KSA

Jeddah-based Saudi pharmaceutical group; diabetes and cardiometabolic portfolio expansion across MENA; Vision 2030-aligned localization.

</atlas?company=Jamjoom%20Pharmaceuticals>

Julphar

Ras Al Khaimah, AE

GCC

Gulf Pharmaceutical Industries (UAE); first GCC manufacturer of recombinant insulin; sovereign-supply anchor for the Gulf diabetes population.

</atlas?company=Julphar>

Hikma Pharmaceuticals

HIK · Amman, JO

MENA

Jordan-headquartered; Levant + MENA + U.S. injectables footprint; broad diabetes-injectable manufacturing relevant to GCC sovereign procurement.

</atlas?company=Hikma%20Pharmaceuticals>

Eva Pharma

Cairo, EG

MENA

Cairo-based generic and branded manufacturer; substantial MENA diabetes-formulary footprint; cross-border supply to GCC sovereign markets.

</atlas?company=Eva%20Pharmaceuticals>

The Indication Intersection — Diabetic Foot Ulcer.

Cross-tagged signal logic

INTERSECTION · DFU

Where the two indications collide.

AimwellBio cross-tags every diabetic foot ulcer signal as both wound-care AND diabetes. Currently tracking 4 cross-tagged signals.

The DFU is the clinical surface where MOH amputation-reduction targets are measured. Single-indication coverage misses it. Combined-vector coverage anchors it.

[Open wound-care signals →](#) [Open diabetes signals →](#)

Live: cross-indication signal pulse.

Showing latest 12 of 182 merged signals

<p>PUBMED DIABETES Dec 30, 2026</p> <p>A geometry-informed continuous 3D IEQ framework enables more accurate dose estimation in stem cell-derived islet transplantation.</p> <p>Lu Y</p> <p>View source ↗</p>	<p>PUBMED WOUND CARE May 07, 2026</p> <p>Electroactive microneedle augmented stem cell therapy in myocardial infarction.</p> <p>Zhang W</p> <p>View source ↗</p>
<p>PUBMED WOUND CARE May 06, 2026</p> <p>Prevalence and incidence of pressure injury in adult patients receiving non-invasive ventilation for acute respiratory failure: a systematic review and meta-...</p> <p>Moretto F</p> <p>View source ↗</p>	<p>MFG WOUND CARE May 06, 2026</p> <p>Our Amniotic Products</p> <p>MiMedx</p> <p>View source ↗</p>
<p>MFG WOUND CARE May 06, 2026</p> <p>Advanced Wound Solutions</p> <p>MiMedx</p> <p>View source ↗</p>	<p>MFG WOUND CARE May 06, 2026</p> <p>Advanced Wound Care Solutions</p> <p>ConvaTec</p> <p>View source ↗</p>
<p>MFG WOUND CARE May 06, 2026</p> <p>Join the Wound Hygiene Movement</p> <p>ConvaTec</p> <p>View source ↗</p>	<p>PUBMED DIABETES May 06, 2026</p> <p>Melatonin improves osteogenic differentiation in a high-glucose environment by activating NRF2 to promote autophagy through the regulation of cross...</p> <p>Zhang J</p> <p>View source ↗</p>
<p>PUBMED DIABETES May 06, 2026</p> <p>Letter to the editor concerning the article: "The diabetic shoulder: association between diabetes mellitus and adhesive capsulitis: a systematic review..."</p> <p>Dong Y</p> <p>View source ↗</p>	<p>PUBMED DIABETES May 06, 2026</p> <p>Human pancreatic ductal cells from non-diabetic donors function as non-professional antigen-presenting cells upon inflammatory cytokine...</p> <p>Erdem N</p> <p>View source ↗</p>

PUBMED

DIABETES

May 06, 2026

Deep learning-powered quantification of endocrine cells and CD3(+) T cells in the natural history of type 1 diabetes.

Kang S

[View source ↗](#)

PUBMED

DIABETES

May 06, 2026

The Nutrition Landscape in Chronic Liver Disease.

McNaLly BB

[View source ↗](#)

[Open Wound Care Report ↗](#)

[Open Diabetes Report ↗](#)

05 · FORWARD TRACK

What we will track for the Kingdom.

Defensible · calibrating

- 01 SFDA approvals on wound-care + diabetes products (currently calibrating).
- 02 MOH formulary changes affecting GLP-1, SGLT2, CGM, AID systems.
- 03 Saudi Vision 2030 amputation-reduction outcome metrics (when MOH releases).
- 04 SPIMACO / Tabuk / Jamjoom procurement cycles via SFDA.
- 05 Cross-border GCC supply (Julphar, Hikma) for sovereign continuity.

METHODOLOGY

This page is generated from a live ingest pipeline (`tools/scout-ingest`) covering FDA openFDA, ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, with CMS LCD, USPTO Patent Center, and manufacturer pipeline pages calibrating. Updated May 07, 2026, 04:23 PM EDT.

Confidence framework: source-backed > pattern-inferred > model-hypothesis > speculative. Sovereign vectors apply additional MOH / SFDA / MOHAP context layers as those data feeds come online.